SCHEMBL4213876

SCHEMBL4213876

O=C(O)N[C@H]1CCN(c2noc(-c3ccccc3)n2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACKR3 P25106 5/20 0.53
▸ USP30 Q70CQ3 2/20 0.43
▸ SMPD3 Q9NY59 1/20 0.43
▸ SCD5 Q86SK9 1/20 0.43
▸ HDAC1 Q13547 2/20 0.42
▸ HDAC6 Q9UBN7 2/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ OPRM1 P35372 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ OGFRL1 Q5TC84 1/20 0.41
▸ CKS1B P61024 2/20 0.40
▸ SKP1 P63208 2/20 0.40
▸ SKP2 Q13309 2/20 0.40
▸ AKT1 P31749 1/20 0.39
▸ S1PR4 O95977 1/20 0.39
▸ S1PR1 P21453 1/20 0.39
▸ S1PR5 Q9H228 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NOTUM Q6P988 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8272245 0.85 CKS1B (0.56) ACKR3USP30OPRM1OPRK1OGFRL1
SCHEMBL14375423 0.85 CKS1B (0.56) ACKR3USP30OPRM1OPRK1OGFRL1
SCHEMBL14349272 0.81 ACKR3 (0.43) ACKR3USP30SMPD3SCD5HDAC1
SCHEMBL8271710 0.79 ACKR3 (0.41) ACKR3USP30HSD11B1OPRK1S1PR1
SCHEMBL4234552 0.79 SMN1; SMN2 (0.48) ACKR3HSD11B1POLB
SCHEMBL4230456 0.77 POLB (0.43) USP30CKS1BSKP1SKP2NOTUM
SCHEMBL23830989 0.74 KDM4E (0.55) TSHR
SCHEMBL18228083 0.74 KDM4E (0.55) TSHR
SCHEMBL15212339 0.73 NOTUM (0.58) ACKR3USP30SCD5NOTUM
SCHEMBL2892698 0.73 DGAT1 (0.47) SCD5HDAC1HDAC6HDAC8S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797094-A4 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2009-06-03 — — EP disclosed
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 — — US disclosed
EP-1797094-A2 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS Merck & Co. Inc. (US) 2007-06-20 — — EP disclosed
WO-2006017409-A2 1,3-DISUBSTITUTED HETEROARYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2006-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293515-A1 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists GRIN2B, GRIN2A, GRIN1 ACKR3 1280/4885USP30 3350/4885SMPD3 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback